US Bancorp’s Cardlytics CDLX Stock Holding History
Bought
Maintained
Sold
Other funds holding CDLX
CIP
6CM
KGAMU
WPM
RC
QOP
US Bancorp's CDLX Position: Q2 2026 in Review
US Bancorp reduced its Cardlytics (CDLX) stake by 66% in Q2 2026, selling an estimated $785 and leaving 54 shares worth $242. The position accounts for ﹤0.01% of the portfolio, ranked #4098.
US Bancorp first reported a position in CDLX in Q2 2020 and has held it in 19 quarters since. The position peaked at $31K in Q2 2021. 42 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.
- US Bancorp held 54 shares of Cardlytics worth $242 as of Q2 2026.
- US Bancorp sold 105 Cardlytics shares in Q2 2026, an estimated $785.
- Cardlytics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4098 holding.
- US Bancorp first reported a position in Cardlytics in Q2 2020 and has held it in 19 quarters since.
- US Bancorp's Cardlytics position peaked at $31K in Q2 2021.
- 42 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.